Population pharmacokinetics of terizidone and cycloserine in patients with drugresistant tuberculosis

dc.contributor.advisorMugabo, Pierre
dc.contributor.authorMulubwa, Mwila
dc.date.accessioned2019-11-08T10:17:25Z
dc.date.accessioned2024-05-15T07:16:48Z
dc.date.available2019-11-08T10:17:25Z
dc.date.available2024-05-15T07:16:48Z
dc.date.issued2019
dc.descriptionDoctor Pharmaceuticae - DPharmen_US
dc.description.abstractIntroduction: Drug-resistant tuberculosis remains a major world health problem and one of the leading cause of death worldwide. Despite adequate adherence to antituberculosis drugs by patients, the emergence of drug-resistance tuberculosis still occurs. This fact implies other factors leading to the emergence of resistant strains of Mycobacterium tuberculosis. A multidrug treatment regimen, which may consist of five to seven different drugs including terizidone, is used in the treatment of drugresistance tuberculosis. Terizidone is part of the multidrug regimen whose pharmacokinetics is scarce in literature and plasma concentration profile unknown. Two molecules of cycloserine joined by terephtalaldehyde moiety makes up a molecule of terizidone, which is thought to undergo complete metabolism into cycloserine in vivo. Additionally, the current literature report that terizidone and cycloserine can be used interchangeably as they are thought to be equivalent. The aim of this thesis was first to develop and validate bioanalytical methods for determination of terizidone and cycloserine in patients’ plasma samples. Secondly, to model population pharmacokinetics of terizidone and cycloserine. Thirdly, to determine the amount of cycloserine resulting from metabolism of terizidone.en_US
dc.identifier.urihttps://hdl.handle.net/10566/15048
dc.language.isoenen_US
dc.publisherUniversity of the Western Capeen_US
dc.rights.holderUniversity of the Western Capeen_US
dc.subjectTerizidoneen_US
dc.subjectDrug-resistant tuberculosisen_US
dc.subjectMetabolismen_US
dc.subjectCycloserineen_US
dc.subjectPopulation pharmacokineticsen_US
dc.titlePopulation pharmacokinetics of terizidone and cycloserine in patients with drugresistant tuberculosisen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
mulubwa_phd_nsc_2019.pdf
Size:
10.29 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description: